LSE:GSKPharmaceuticals
GSK’s US$10.6b Nuvalent Purchase Recasts Oncology And Future Revenue Mix
GSK (LSE:GSK) has agreed to acquire Nuvalent Inc. in a cash deal valued at US$10.6b.
The transaction brings two late stage non small cell lung cancer candidates with FDA Breakthrough Therapy and Orphan Drug designations into GSK's oncology pipeline.
Commercial launches for these tyrosine kinase inhibitors are targeted for late 2026, pending regulatory approvals.
GSK, trading around £19.035 per share, has shown strong share price performance, with the stock up 30.9% over the past year and...